RESEARCH PEPTIDE FUNDAMENTALS / MATRIX
Four Peptides, Four Different Kinds of Evidence
How a repair peptide, a coenzyme, an approved drug, and an immune peptide compare on mechanism, evidence maturity, regulatory status, and the single caution that matters most for each.
The short version
This page lines up BPC-157, NAD+, semaglutide, and Thymosin Alpha-1 on the dimensions that matter most for reading healthspan and cellular-aging research: what class of molecule each is, what it is most studied for, how mature its human evidence is, its regulatory status, and its single most important caution. The headline is simple but easy to miss: these four are not evidentially interchangeable. Semaglutide has multi-thousand-participant randomized trials and FDA approval behind it. NAD+ precursors have solid dosing-safety data but an unsettled translation to clinical outcomes. Thymosin Alpha-1 has decades of use abroad but a recent null result in its largest, most rigorous trial. BPC-157's human record is three small pilot studies. None of this is medical advice, and no dose here is a recommendation.
The comparison matrix
| Dimension | BPC-157 | NAD+ | Semaglutide | Thymosin Alpha-1 |
|---|---|---|---|---|
| Class of molecule | Synthetic pentadecapeptide (gastric-juice-derived) | Redox coenzyme / cellular metabolite | GLP-1 receptor agonist peptide | Thymic immunomodulatory peptide |
| Most studied for | Tissue repair, angiogenesis, gut-lining protection | Cellular energy metabolism, age-related decline | Weight management, glycemic control, CV/kidney protection | Immune restoration, chronic viral infection, sepsis |
| Evidence maturity | Overwhelmingly rodent; 3 small human pilot studies [1][2] | Multiple human RCTs on precursors; hard clinical outcomes unproven [6][7][10] | Large-scale RCTs across multiple indications; FDA-approved [13][14][15][16] | Decades of international use; largest recent RCT was null [18][19] |
| Administration studied | IV, IM, oral, subcutaneous (research contexts) | Oral (NMN/NR), IV/injectable | Once-weekly subcutaneous injection; once-daily oral tablet | Subcutaneous injection |
| Regulatory status | Not approved anywhere; sold as research chemical | Sold as dietary supplement; NMN status contested by FDA | FDA-approved (multiple indications) | Approved in 35+ countries; not approved in the US |
| Key caution | Human evidence extremely thin; theoretical cancer/angiogenesis concern [4] | Translation from raised NAD+ to clinical benefit unproven [6] | GI intolerance; weight regain after stopping [17] | Largest recent trial found no mortality benefit [18] |
Class of molecule
The four compounds span four genuinely different categories, not four variations on one theme. BPC-157 is a synthetic 15-amino-acid peptide derived from a sequence in human gastric juice, prized for stability against digestive breakdown. NAD+ is not a peptide at all — it is a small-molecule redox coenzyme every cell already produces, built from two joined nucleotides. Semaglutide is a 31-amino-acid engineered analogue of the natural gut hormone GLP-1, modified with a fatty-acid side chain for a week-long half-life. Thymosin Alpha-1 is a 28-amino-acid immune-signaling peptide naturally cleaved from a thymus-derived precursor protein. Reading them side by side is a useful exercise precisely because 'research peptide' turns out to describe a very wide range of underlying chemistry.
Most-studied application
BPC-157's animal literature centers on tissue repair — gut lining, tendons, ligaments, and blood-vessel growth via angiogenesis [4][5]. NAD+ research centers on cellular energy metabolism and the well-documented age-related decline in NAD+ levels, with human trials focused on raising blood NAD+ via oral precursors [6][7][10]. Semaglutide's trial program has expanded well beyond its original diabetes indication into weight management, cardiovascular event reduction, and kidney protection [14][15][16]. Thymosin Alpha-1's clinical trials cluster around chronic viral hepatitis, cancer immunotherapy support, and sepsis, with the most rigorous recent data coming from the sepsis literature [18][22].
Evidence maturity
This is where the four genuinely separate. Semaglutide sits at the deep end: multi-thousand-participant randomized trials across several indications, years of pharmacovigilance data, and FDA approval [14][15][16][17]. NAD+ precursor trials are smaller — dozens to low hundreds of participants — but methodologically solid, with consistent dose-dependent NAD+ elevation and a good safety record; what remains unproven is translation to a hard clinical outcome, a gap a 2025 review states directly [6]. Thymosin Alpha-1 has decades of accumulated international clinical use, but its most rigorous recent trial, a 1,106-patient phase 3 sepsis study, came back null [18], and much of the remaining evidence base is smaller, single-region, or open-label. BPC-157 sits at the thin end: an extensive rodent literature, but only three small human pilot studies as of the most recent narrative review [2].
Regulatory status
Semaglutide is an FDA-approved prescription medicine. NAD+ and its common precursors are sold as dietary supplements, though the FDA has separately taken the position that NMN is excluded from the dietary-supplement definition, creating marketplace uncertainty. Thymosin Alpha-1 (thymalfasin) is an approved drug in more than 35 countries but has no US marketing approval [19]. BPC-157 is not approved as a medicine anywhere and is sold strictly as a research chemical not intended for human consumption.
Key caution
Each compound carries a defining caveat. For BPC-157, it is simply that the human evidence is extremely thin, with a theoretical — not demonstrated — concern about its pro-angiogenic mechanism in the context of active cancer [2][4]. For NAD+, it is that raising blood levels via NMN or NR is well established, but translating that into a clinically meaningful outcome is not [6]; a separate, distinct caution applies to IV/injectable NAD+, which carries a documented contamination recall unrelated to the molecule itself. For semaglutide, it is gastrointestinal intolerance during dose escalation and the well-documented pattern of weight regain after stopping, framing it as chronic rather than curative therapy [17]. For Thymosin Alpha-1, it is that the largest and most methodologically rigorous trial conducted to date — a 2025 phase 3 sepsis study — found no mortality benefit, tempering expectations built on smaller, earlier data [18].